Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

About the Enobosarm Phase 2b clinical trial About Enobosarm Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 ENABLAR-2 clinical trial of * Wegovy® is a r ...